Skip to main content
Top
Published in: European Journal of Medical Research 1/2018

Open Access 01-12-2018 | Research

Treatment of onychomycosis using a 1064-nm diode laser with or without topical antifungal therapy: a single-center, retrospective analysis in 56 patients

Authors: G. C. Weber, P. Firouzi, A. M. Baran, E. Bölke, H. Schrumpf, B. A. Buhren, B. Homey, P. A. Gerber

Published in: European Journal of Medical Research | Issue 1/2018

Login to get access

Abstract

Background

Currently available treatment options for onychomycosis such as topical and systemic antifungals are often of limited efficacy, difficult to administer or associated with relevant side effects. Non-ablative laser therapy is proposed to represent a safe alternative without the disadvantages of drugs. Yet, to date, the efficacy of laser therapy for onychomycosis is discussed controversially. Against this background, we performed a systematic retrospective analysis of our clinical experience of 4 years of onychomycosis treatment applying a long-pulsed 1.064-nm diode laser.

Methods

We retrospectively evaluated the records of 56 patients with microscopic and culturally proven onychomycosis affecting a toenail of the hallux and other toes, who had been treated with a long-pulsed 1.064-nm diode laser (FOX, A.C.R. Laser GmbH, Nuremberg) during the time period of July 2013–December 2016 with or without concomitant topical antifungals. Thereof, 27 patients received laser treatment and 29 patients received laser treatment in combination with local antifungals. We conducted a mean of 3.9 laser treatments at 2–6-week intervals. The primary endpoint of our analysis was clinical improvement; secondary endpoints were complete remission of fungal pathogens in fungal culture and in microscopy.

Results

Clinical improvement was achieved in 56% of patients treated with laser only after a mean of 4.5 treatments and in 69% of patients treated with laser in combination with topical antifungals after a mean of 3.6 treatments. Cultural healing was detected in 63% of patients treated with laser only after a mean of 5.4 treatments, vs. 86% of patients treated with laser and concomitant topical antifungals after a mean of 4.8 treatments. Microscopic healing (complete healing) with the absence of fungal pathogens was achieved in 11% of patients after a mean of 4.7 treatments with laser only, vs. 21% of patients treated with laser and concomitant topical antifungals after a mean of 4 treatments. No relevant adverse effects were observed.

Conclusions

The 1.064-nm diode laser is an effective and safe option for the treatment of onychomycosis. Of note, the combination with topical antifungals will increase overall treatment efficacy and reduce the time to healing. Particularly, patients with contraindications against systemic antifungals may benefit from this multimodal therapeutic approach. Our data, moreover, suggest that treatment efficacy is positively correlated with the total number of laser treatments.
Literature
1.
go back to reference Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;2000:641–8.CrossRef Ghannoum MA, Hajjeh RA, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol. 2000;2000:641–8.CrossRef
2.
go back to reference Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population—a literature study. JEADV. 2014;2014:1480–91. Sigurgeirsson B, Baran R. The prevalence of onychomycosis in the global population—a literature study. JEADV. 2014;2014:1480–91.
3.
go back to reference Gupta AK, Nakrieko K-A. Molecular determination of mixed infections of dermatophytes and nondermatophyte molds in individuals with onychomycosis. J Am Podiatr Med Assoc. 2014;2014:330–6.CrossRef Gupta AK, Nakrieko K-A. Molecular determination of mixed infections of dermatophytes and nondermatophyte molds in individuals with onychomycosis. J Am Podiatr Med Assoc. 2014;2014:330–6.CrossRef
4.
go back to reference Scher R, Rich P, Elewski B, Pariser D. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg. 2013;2013:S2–4.CrossRef Scher R, Rich P, Elewski B, Pariser D. The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg. 2013;2013:S2–4.CrossRef
5.
go back to reference Scherer WP, McCreary JP, Hayes WW. The diagnosis of onychomycosis in a geriatric population: a study of 450 cases in South Florida. J Am Podiatr Med Assoc. 2001;2001:456–64.CrossRef Scherer WP, McCreary JP, Hayes WW. The diagnosis of onychomycosis in a geriatric population: a study of 450 cases in South Florida. J Am Podiatr Med Assoc. 2001;2001:456–64.CrossRef
6.
go back to reference Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther. 2007;20:31–46.CrossRef Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther. 2007;20:31–46.CrossRef
7.
go back to reference Elewski B. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11:415–29.CrossRef Elewski B. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11:415–29.CrossRef
8.
go back to reference Schemer A. Update: medical treatment of onychomycosis. Dermatol Ther. 2012;2012:582–93.CrossRef Schemer A. Update: medical treatment of onychomycosis. Dermatol Ther. 2012;2012:582–93.CrossRef
9.
go back to reference AWMF. Onychomykose, ICD-10 Ziffer B35.1. Leitlinien der Deutschen Dermatologischen Gesellschaft und der Deutschsprachigen Mykologischen Gesellschaft; 2006. AWMF. Onychomykose, ICD-10 Ziffer B35.1. Leitlinien der Deutschen Dermatologischen Gesellschaft und der Deutschsprachigen Mykologischen Gesellschaft; 2006.
10.
go back to reference Brenner MA, Harkless LB, Mendicino RW, Page JC. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes, A multicenter, open-label study. J Am Podiatr Med Assoc. 2007;97:195–202.CrossRef Brenner MA, Harkless LB, Mendicino RW, Page JC. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes, A multicenter, open-label study. J Am Podiatr Med Assoc. 2007;97:195–202.CrossRef
12.
go back to reference Verrier J, Bontems O, Baudraz-Rosselet F, Monod M. Oral terbinafine and itraconazole treatments against dermatophytes appear not to favor the establishment of Fusarium spp. in nail. Dermatology. 2014;228:225–32.CrossRef Verrier J, Bontems O, Baudraz-Rosselet F, Monod M. Oral terbinafine and itraconazole treatments against dermatophytes appear not to favor the establishment of Fusarium spp. in nail. Dermatology. 2014;228:225–32.CrossRef
13.
go back to reference Gupta AK, Uro M, Cooper EA. Onychomycosis therapy, past, present, future. J Drugs Dermatol. 2010;2010:1109–13. Gupta AK, Uro M, Cooper EA. Onychomycosis therapy, past, present, future. J Drugs Dermatol. 2010;2010:1109–13.
15.
go back to reference Gupta AK, Versteeg SG. A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. JEADV. 2017;31:1111–8.PubMed Gupta AK, Versteeg SG. A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. JEADV. 2017;31:1111–8.PubMed
16.
go back to reference Vural E, Winfield HL, Shingleton AW, Horn TD, Shafirstein G. The effects of laser irradiation on Trichophyton rubrum growth. Lasers Med Sci. 2008;2008:349–53.CrossRef Vural E, Winfield HL, Shingleton AW, Horn TD, Shafirstein G. The effects of laser irradiation on Trichophyton rubrum growth. Lasers Med Sci. 2008;2008:349–53.CrossRef
17.
go back to reference Wanitphakdeedecha R, Thanomkitti K, Bunyaratavej S, Manuskiatti W. Efficacy and safety of 1064-nm Nd:YAG laser in treatment of onychomycosis. J Dermatol Treat. 2016;2016:75–9.CrossRef Wanitphakdeedecha R, Thanomkitti K, Bunyaratavej S, Manuskiatti W. Efficacy and safety of 1064-nm Nd:YAG laser in treatment of onychomycosis. J Dermatol Treat. 2016;2016:75–9.CrossRef
18.
go back to reference Hashimoto T, Blumenthal HJ. Survival and resistance of Trichophyton mentagrophytes arthrospores. Appl Environ Microbiol. 1978;35:274–7.PubMedPubMedCentral Hashimoto T, Blumenthal HJ. Survival and resistance of Trichophyton mentagrophytes arthrospores. Appl Environ Microbiol. 1978;35:274–7.PubMedPubMedCentral
19.
go back to reference Carney C, Cantrell W, Warner J, Elewski B. Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser. J Am Acad Dermatol. 2013;2013:578–82.CrossRef Carney C, Cantrell W, Warner J, Elewski B. Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser. J Am Acad Dermatol. 2013;2013:578–82.CrossRef
20.
go back to reference Landthaler M, Haina D, Brunner R, Waidelich W, Braun-Falco O. Effects of argon, dye, and Nd:YAG lasers on epidermis, dermis, and venous vessels. Lasers Surg Med. 1986;1986:87–93.CrossRef Landthaler M, Haina D, Brunner R, Waidelich W, Braun-Falco O. Effects of argon, dye, and Nd:YAG lasers on epidermis, dermis, and venous vessels. Lasers Surg Med. 1986;1986:87–93.CrossRef
21.
go back to reference Gupta AK, Simpson FC, Heller DF. The future of lasers in onychomycosis. J Dermatol Treat. 2016;27:167–72.CrossRef Gupta AK, Simpson FC, Heller DF. The future of lasers in onychomycosis. J Dermatol Treat. 2016;27:167–72.CrossRef
22.
go back to reference Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science. 1983;220:524–7.CrossRef Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science. 1983;220:524–7.CrossRef
23.
go back to reference Hees H, Raulin C, Bäumler W. Laser treatment of onychomycosis: an in vitro pilot study. J Dtsch Dermatol Ges. 2012;2012:913–8. Hees H, Raulin C, Bäumler W. Laser treatment of onychomycosis: an in vitro pilot study. J Dtsch Dermatol Ges. 2012;2012:913–8.
24.
go back to reference Karsai S, Jäger M, Oesterhelt A, et al. Treating onychomycosis with the short-pulsed 1064-nm-Nd:YAG laser: results of a prospective randomized controlled trial. JEADV. 2017;2017:175–80. Karsai S, Jäger M, Oesterhelt A, et al. Treating onychomycosis with the short-pulsed 1064-nm-Nd:YAG laser: results of a prospective randomized controlled trial. JEADV. 2017;2017:175–80.
25.
go back to reference Renner R, Grüsser K, Sticherling M. 1,064-nm diode laser therapy of onychomycosis: results of a prospective open treatment of 82 toenails. Dermatology. 2015;2015:128–34.CrossRef Renner R, Grüsser K, Sticherling M. 1,064-nm diode laser therapy of onychomycosis: results of a prospective open treatment of 82 toenails. Dermatology. 2015;2015:128–34.CrossRef
26.
go back to reference Hollmig ST, Rahman Z, Henderson MT, Rotatori RM, Gladstone H, Tang JY. Lack of efficacy with 1064-nm neodymium:yttrium-aluminum-garnet laser for the treatment of onychomycosis: a randomized, controlled trial. J Am Acad Dermatol. 2014;2014:911–7.CrossRef Hollmig ST, Rahman Z, Henderson MT, Rotatori RM, Gladstone H, Tang JY. Lack of efficacy with 1064-nm neodymium:yttrium-aluminum-garnet laser for the treatment of onychomycosis: a randomized, controlled trial. J Am Acad Dermatol. 2014;2014:911–7.CrossRef
27.
go back to reference Landsman AS, Robbins AH. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc. 2012;102:169–71.CrossRef Landsman AS, Robbins AH. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc. 2012;102:169–71.CrossRef
28.
go back to reference Landsman AS, Robbins AH, Angelini PF, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc. 2010;100:166–77.CrossRef Landsman AS, Robbins AH, Angelini PF, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc. 2010;100:166–77.CrossRef
29.
go back to reference Waibel J, Wulkan AJ, Rudnick A. Prospective efficacy and safety evaluation of laser treatments with real-time temperature feedback for fungal onychomycosis. J Drugs Dermatol. 2013;2013:1237–42. Waibel J, Wulkan AJ, Rudnick A. Prospective efficacy and safety evaluation of laser treatments with real-time temperature feedback for fungal onychomycosis. J Drugs Dermatol. 2013;2013:1237–42.
30.
go back to reference Rivers JK, Vestvik BJ, Berkowitz J. Real-world efficacy of 1064-nm Nd:YAG laser for the treatment of onychomycosis. J Cutan Med Surg. 2017;2017:108–13.CrossRef Rivers JK, Vestvik BJ, Berkowitz J. Real-world efficacy of 1064-nm Nd:YAG laser for the treatment of onychomycosis. J Cutan Med Surg. 2017;2017:108–13.CrossRef
31.
go back to reference Okan G, Tarikci N, Gokdemir G. The effect of long-pulsed Nd:YAG laser for the treatment of onychomycosis. J Am Podiatr Med Assoc. 2017;2017:54–9.CrossRef Okan G, Tarikci N, Gokdemir G. The effect of long-pulsed Nd:YAG laser for the treatment of onychomycosis. J Am Podiatr Med Assoc. 2017;2017:54–9.CrossRef
32.
go back to reference Ortiz AE, Truong S, Serowka K, Kelly KM. A 1,320-nm Nd:YAG laser for improving the appearance of onychomycosis. Dermatol Surg. 2014;40:1356–60.CrossRef Ortiz AE, Truong S, Serowka K, Kelly KM. A 1,320-nm Nd:YAG laser for improving the appearance of onychomycosis. Dermatol Surg. 2014;40:1356–60.CrossRef
33.
go back to reference Xu Y, Miao X, Zhou B, Luo D. Combined oral terbinafine and long-pulsed 1,064-nm Nd:YAG laser treatment is more effective for onychomycosis than either treatment alone. Dermatol Surg. 2014;40:1201–7.CrossRef Xu Y, Miao X, Zhou B, Luo D. Combined oral terbinafine and long-pulsed 1,064-nm Nd:YAG laser treatment is more effective for onychomycosis than either treatment alone. Dermatol Surg. 2014;40:1201–7.CrossRef
34.
go back to reference Li Y, Yu S, Xu J, Zhang R, Zhao J. Comparison of the efficacy of long-pulsed Nd:YAG laser intervention for treatment of onychomycosis of toenails or fingernails. J Drugs Dermatol. 2014;2014:1258–63. Li Y, Yu S, Xu J, Zhang R, Zhao J. Comparison of the efficacy of long-pulsed Nd:YAG laser intervention for treatment of onychomycosis of toenails or fingernails. J Drugs Dermatol. 2014;2014:1258–63.
35.
go back to reference Paul C, Coustou D, Lahfa M, et al. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis. Dermatology. 2013;2013:157–64. Paul C, Coustou D, Lahfa M, et al. A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis. Dermatology. 2013;2013:157–64.
36.
go back to reference Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43:S70–80.CrossRef Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43:S70–80.CrossRef
37.
go back to reference Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol. 2004;150:537–44.CrossRef Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol. 2004;150:537–44.CrossRef
38.
go back to reference Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005;2005:299–306. Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag. 2005;2005:299–306.
39.
go back to reference Okamoto J, Fukunami M, Kioka H. Frequent premature ventricular contractions induced by itraconazole. Circ J. 2007;2007:1323–5.CrossRef Okamoto J, Fukunami M, Kioka H. Frequent premature ventricular contractions induced by itraconazole. Circ J. 2007;2007:1323–5.CrossRef
40.
go back to reference Bangsgaard N, Saunte DM, Folkenberg M, Zachariae C. Serious adverse events reporting on systemic terbinafine: a Danish register-based study. Acta Derm Venereol. 2011;2011:358–9.CrossRef Bangsgaard N, Saunte DM, Folkenberg M, Zachariae C. Serious adverse events reporting on systemic terbinafine: a Danish register-based study. Acta Derm Venereol. 2011;2011:358–9.CrossRef
41.
go back to reference Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;2001:1766–7.CrossRef Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;2001:1766–7.CrossRef
42.
go back to reference Hees H, Jäger MW, Raulin C. Treatment of onychomycosis using the 1 064 nm Nd:YAG laser: a clinical pilot study. J Dtsch Dermatol Ges. 2014;2014:322–9. Hees H, Jäger MW, Raulin C. Treatment of onychomycosis using the 1 064 nm Nd:YAG laser: a clinical pilot study. J Dtsch Dermatol Ges. 2014;2014:322–9.
43.
go back to reference Leverone AP, Guimarães DA, Bernardes-Engemann AR, Orofino-Costa R. Partial necrosis of the hallux in a patient treated with laser for onychomycosis, is this procedure really worthwhile? Dermatol Surg. 2015;41:869–72.CrossRef Leverone AP, Guimarães DA, Bernardes-Engemann AR, Orofino-Costa R. Partial necrosis of the hallux in a patient treated with laser for onychomycosis, is this procedure really worthwhile? Dermatol Surg. 2015;41:869–72.CrossRef
Metadata
Title
Treatment of onychomycosis using a 1064-nm diode laser with or without topical antifungal therapy: a single-center, retrospective analysis in 56 patients
Authors
G. C. Weber
P. Firouzi
A. M. Baran
E. Bölke
H. Schrumpf
B. A. Buhren
B. Homey
P. A. Gerber
Publication date
01-12-2018
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2018
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-018-0340-y

Other articles of this Issue 1/2018

European Journal of Medical Research 1/2018 Go to the issue